Argatroban in HIT type II and acute coronary syndrome

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue SUPPL. 3, 2002, Pages 46-55

  Lewis, Bruce E ^a,b   Walenga, Jeanine M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Catholic Health Partners   (United States)

Author keywords

Acute coronary syndrome; Argatroban; Heparin antibody; Thrombin inhibitor

Indexed keywords

ANCROD; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DANAPAROID; DEXTRAN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LEPIRUDIN; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING TENDENCY; CORONARY ARTERY THROMBOSIS; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CORONARY DISEASE; HUMANS; MYOCARDIAL INFARCTION; PIPECOLIC ACIDS; THROMBOCYTOPENIA;

EID: 0344515648     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069109     Document Type: Review

References (66)

1. Jeske W, Walenga JM, Lewis BE, Fareed J: Pharmacology of argatroban. Exp Opin Invest Drugs 1999;8:625-654.
2. Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan PW, Kogan TP, McKinney AA, Schwarz RP: Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997;23:503-516.
3. Bush LR: Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 1991;9:247-263.
4. Hijikata-Okunomiya A, Okamoto S: A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost 1992;18:135-149.
5. Berry CN, Girard D, Lochot S, Lecoffre C: Antithrombotic actions of argatroban in rat models of venous, mixed and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharm 1994;113:1209-1214.
6. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D: Antibodies to macro-molecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost 1995;73:21-28.
7. Greinacher A, Pötzsch B, Amiral J, Cummel V, Eichner A, Mueller-Eckhardt C: Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multi-molecular PF-4 heparin complex as the major antigen. Thromb Haemost 1994;71:247-251.
8. Kelton, JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-3239.
9. Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL: On the role of platelet FcRIIA phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995;74:1564-1572.
10. Aster RH: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:1374-1376.
11. Greinacher A, Michels I, Liebenhoff U, Presek P, Mueller-Eckhardt C: Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative charge of highly sulfated oligosaccharides. Br J Haematol 1993;84:711-716.
12. Walenga JM, Koza MJ, Lewis BE, Pifarré R: Relative heparin induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996;2(suppl 1):S21-S27.
13. Cines DB, Tomaski A, Tannenbaum S: Immune endothelial-cell injury in heparin associated thrombocytopenia. N Engl J Med 1987; 316:581-589.
14. Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1995;93:81-88.
15. Herbert J-M, Savi P, Jeske WP, Walenga JM: Effect of SR121566A, a potent GPIIb/IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 1998;80:326-331.
16. Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y: Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001;97:3300-3302.
17. Jeske WP, Walenga JM, Szatkowski E, Ero M, Herbert JM, Bakhos M: Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 1997;88:271-281.
18. Warkentin TE, Hayward CPM, Boshkov CK, Santos AV, Sheppard JI, Bode AP, Kelton JG: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699.
19. Walenga JM, Lewis BE, Jeske WP, Leya F, Wallis DE, Bakhos M, Fareed, J: Combined thrombin and platelet inhibition treatment for HIT patients. Hämostaseologie 1999;19:128-133.
20. Jeske WP, Vasaiwala S, Schlenker R, Wallis E, Walenga JM: Leukocyte activation in heparin-induced thrombocytopenia (abstract). Blood 2000;96:29b.
21. Walenga JM, Jeske WP, Messmore HL: Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2000;10(suppl 1):S13-S20.
22. Lewis BE, Walenga JM, Wallis DE: Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997;23:197-202.
23. Messmore HL, Upadhyay G, Farid S, Parachuri R, Wehrmacher W, Godwin J: Heparin-induced thrombocytopenia and thrombosis in cardiovascular surgery; in Pifarré R (ed): New Anticoagulants for the Cardiovascular Patient. Philadelphia, Hanley & Belfus, 1993, pp 83-94.
24. Walenga JM, Lewis BE, Hoppensteadt DA, Fareed J, Bakhos M: Management of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Thromb Hemost 1997;3(suppl 1):S53-S63.
25. Moberg P, Geary V, Sheikh M: Heparin-induced thrombocytopenia: A possible complication of heparin-coated pulmonary artery catheters. J Cardiothorac Vasc Anesth 1990;4:266.
26. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarré R, Moran JF: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629-635.
27. Warkentin T, Kelton J: A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
28. Walenga JM, Jeske WP, Wood JJ, Ahmad S, Lewis BE, Bakhos M: Laboratory tests for heparin-induced thrombocytopenia: A multicenter study. Semin Hematol 1999;36(suppl 1):22-28.
29. Walenga JM, Jeske WP, Fasanella AR, Wood JJ, Bakhos M: Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemostas 1999;25(suppl 1):43-49.
30. Lindhoff-Last E, Eichler P, Stein M, Plagemann J, Gerdsen F, Wagner R, Ehrly AM, Bauersachs R: A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 2000;97:387-393.
31. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
32. Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD: Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-1246.
33. Prechel M, Bano A, Drenth AF, Messmore HL, Walenga JM: Assay selection and interpretation for laboratory testing of heparin-induced thrombocytopenia: Diagnostic implications. Blood 2001;98:36a.
34. Wallis DE, Quintos R, Wehrmacher W, Messmore H: Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest 1999;116:1333-1338.
35. Rao RC, Lewis BE, Johnson SA: Thrombolytic experience for treatment of thrombosis in patients with post-operative heparin-induced thrombocytopenia (abstract). Blood 1995;86(suppl 1):551a.
36. Cohen JI, Cooper MR, Greenberg CS: Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch Intern Med 1985;135:1725-1726.
37. Cole CW, Bormanis J: Ancrod: A practical alternative to heparin. J Vasc Surg 1988;8:59-63.
38. Lewis BE, Leya FS, Wallis D, Grassman E: Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can J Cardiol 1994;10:559-561.
39. Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993;70:554-561.
40. Haas S, Walenga JM, Jeske WP, Fareed J: Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clin Appl Thromb Hemost 1999;5:52-59.
41. Greinacher A, Feigl M, Mueller-Eckhardt C: Cross-reactivity studies between sera of patients with heparin associated thrombocytopenia and a new low molecular weight heparin, reviparin. Thromb Haemost 1994;72:644-645.
42. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, for the ARG-911 Study Investigators: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
43. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Pötzsch B, for the HIT Investigators Group: Recombinant hirudin (lepirudin) provides safe and effective anti-coagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99:73-80.
44. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, Eichler P, Volpel H, Pötzsch B, Luz M, for the Heparin-Associated Thrombocytopenia Study (HAT) investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-593.
45. Izawa O, Katsuki M, Komatsu T, Iida S: Pharmacokinetics studies of argatroban (MD-805) in human - Concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion (in Japanese). Jpn Pharmacol Ther 1986;14 (suppl 5):251-263.
46. Bergougnan L, Moore N, Brohier S: Pharmacodynamic and pharmacokinetic profile of argatroban (1 mg/ml alcohol solution) in healthy man. J Clin Pharmacol 1998;38:878.
47. Swan SK, Hursting MJ: The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329.
48. Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ: Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000;20:756-770.
49. Eichler P, Friesen H-J, Lubenow N, Jaeger B, Greinacher A: Anti-hirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood 2000;96:2373-2378.
50. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE: Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002; 105:401-405.
51. Walenga JM, Fasanella AR, Iqbal O, Hoppensteadt DA, Ahmad S, Wallis DE, Bakhos M: Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999;25(suppl 1):61-66.
52. Ahmad S, Ahsan A, Iqbal O, Hoppensteadt DA, Lewis BE, Walenga JM, Fareed J: Pharmacokinetics and pharmacodynamics of argatroban as studied by HPLC and functional methods: Implications in the monitoring and dosage-optimizations in cardiovascular patients. Clin Appl Thromb Hemost 1998;4:243-249.
53. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK: Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85:435-440.
54. Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP: The interventional normalization ratio during concurrent warfarin and argatroban anticoagulation differential contributions of each agent and effects of the choice of the thromboplastin used. Clin Chem 1999;45:409-412.
55. Haas S, Walenga JM, Jeske WP, Fareed J: Heparin-induced thrombocytopenia: The role of platelet activation and therapeutic implications. Semin Thromb Hemost 1999;25(suppl 1):67-75.
56. Lewis BE, Ferguson JJ, Grassman ED, Fareed J, Walenga JM, Joffrion JL, Wrona L, Johnson SA, Schwarz RP, McKiernan T: Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996;8:410-417.
57. Lewis BE, Iqbal O, Hoppensteadt D, Ahsan A, Ahmad S, Messmore HL, Schwarz RP, Walenga JM: Clinical pharmacokinetic and pharmacodynamic studies on argatroban to optimize the anticoagulant dosage in interventional cardiovascular procedures (abstract). Thromb Haemost 1997(suppl);492.
58. Lewis BE, Rangel Y, Fareed J: The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: A case report. Angiology 1998;49:61-67.
59. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F, ARG-216/310/311 Study Investigators: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57:177-184.
60. Itoh T, Nonogi H, Miyazaki S, Itoli A, Daikoko S: Local delivery of argatroban using drug delivery device 'dispatch' in the prevention of restenosis following coronary angioplasty trial (40-CAT): Result of the prospective randomized pilot study. Circulation 1997;96:3635.
61. Kobayashi H, Suzuki S, Sakamoto S, Matsuo T: Argatroban, a direct thrombin inhibitor versus heparin during and after percutaneous transluminal coronary angioplasty (PTCA) (abstract). Thromb Haemost 1997(suppl);494.
62. Herrman JP, Suryapranata H, den Heijer P, Gabriel L, Kutryk MJB, Serruys PW: Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study. J. Thromb Thrombolysis 1996;3:367-375.
63. Lewis BE, Grassman ED, Wrona L, Rangel Y: Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:54-58.
64. Kobayashi S, Tazaki Y: Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997;23:531-534.
65. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, Dutra OP, Bazzino O, Viamonte VM, Norbady R, Liprandi AS, Massey TJ, Dinsmore R, Schwarz RP: A multi-center, randomized study of argatroban versus heparin as adjunct to tPA in acute MI: MI with novastan and tPA study (MINT). J Am Coll Cardiol 1999;33:1879-1885.
66. Vermeer F, Vahanian A, Fels PW, Besse P, Muller E, van deWerf F, Fitzgerald D, Darius H, Puel J, Garrigou D, Simoons ML: Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study. J Thromb Thrombolysis 2000;10:233-240.